Fair Value Calculator Fair Value Calculator
EN DE

SULABEN (SULABEN) Fair Value & Analysis

IN · Market cap ₹286M

S SULABEN SULABEN · BSE
Price₹2.85
Fair Value₹1.72
Upside-39.6%
Quality62/100
Watch SULABEN for free — get notified when fair value or trend changes. Watch for free
Evidence: Medium Range ₹1.29 – ₹2.16

Fair value as of: Jul 6, 2026

From 22 valuation models · updated today

Share price −5.6% over the past month.

Price vs Fair Value (12 months)

₹3.70 ₹2.20 Fair Value ₹1.72 Jul 2025 Jul 2026

12‑month range ₹2.20 – ₹3.70 · fair‑value band ₹1.29 – ₹2.16 · the ₹2.85 price screens above the ₹1.72 fair value. As of Jul 6, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

SULABEN (SULABEN) currently trades at ₹2.85, while our model-based Fair Value estimate is ₹1.72 — implying the stock looks roughly 39.6% overvalued today. We read business quality at 62/100 (solid quality). Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

Over the trailing twelve months, SULABEN generated revenue of ₹40.8M at a net margin of 21.2%. Revenue declined 12.2% year over year. It earns a return on equity of 3.8%. Net debt stands at ₹15.2M. Fundamentals as of Jul 6, 2026

Our scenario range runs from ₹1.29 (bear case) to ₹2.16 (bull case); at ₹2.85, the current price sits above that range. The share trades about 32% below its 52-week high and 40% above its 52-week low, currently above its 200-day average.

Key figures & financial health

Revenue (TTM) ₹40.8M
Revenue growth (YoY) -12.2%
Net margin 21.2%
Return on equity 3.8%
Free cash flow ₹17.7M FY2026
P/E ratio 31.7
More key figures
Operating margin -62.4%
EPS (TTM) ₹0.0900
EPS growth (YoY) +25.1%
Net debt ₹15.2M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 6, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

SULABEN reported revenue of ₹37.9M in FY2026 versus ₹33.5M in FY2022, a compound +3.2%/yr. Reported net income was ₹8.7M in FY2026, compounding −0.9%/yr from FY2022.

Revenue +3.2%/yr
FY22 ₹33.5M
FY23 ₹36.0M
FY24 ₹29.0M
FY25 ₹48.8M
FY26 ₹37.9M
Net income −0.9%/yr
FY22 ₹9.0M
FY23 ₹11.4M
FY24 ₹14.2M
FY25 ₹24.6M
FY26 ₹8.7M

Is SULABEN fairly valued? → Check now

🧮 Run the numbers yourself — free valuation calculators
📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog — it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "SULABEN Fair Value". https://www.fairvalue-calculator.com/stock/SULABEN

Explore undervalued stocks

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is SULABEN (SULABEN) undervalued?
As of Jul 6, 2026, our model estimates a fair value of ₹1.72 versus a price of ₹2.85 — about −40% (overvalued). Model-based estimate, not financial advice.
What is the fair value of SULABEN?
Our model-based fair value for SULABEN is ₹1.72 (as of Jul 6, 2026), built from audited fundamentals. The current price is ₹2.85.
What is the quality score of SULABEN?
SULABEN has a Quality Score of 62/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of SULABEN (SULABEN)?
SULABEN reported trailing-twelve-month revenue of about ₹40.8M (latest available figure, as of Jul 6, 2026).
What is the net profit margin of SULABEN?
The net profit margin of SULABEN is about 21.2%, meaning it keeps roughly 21.2% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.